Apollo Hospitals, Asia’s foremost integrated healthcare services provider today announced a unique collaboration with ConnectedLife, leaders in the application of motor state diagnostics, to integrate Apollo‘s (further developments) AICVD tool with ConnectedLife’s digital solutions for wellness, condition management and other health-focused applications.
The AICVD tool can predict the risk of cardiovascular disease. This will empower healthcare providers with the tools to predict the risk of cardiac disease in their patients and initiate intervention early enough to make a real difference.
The clinical integration was demonstrated during the online event to announce the collaboration. The cardiac risk scoring tool is remarkable for its speed in processing data and accuracy in predicting the probability of a patient developing coronary disease.
Using the tool, physicians are enabled to deliver proactive, pre-emptive and preventive care for at-risk individuals, improving lives, while mitigating future risks to life and lessen the pressure on healthcare systems.
ConnectedLife is a Singapore headquartered health-tech and partners with Fitbit to create compelling wearable-based solutions for wellness, condition management and other health-focused applications.
The ConnectedLife platform captures and analyses Fitbit wearable devices and patient-reported data to provide health and wellness insights for individuals and connected population health stakeholders.
The unique research and development collaboration between Apollo Hospitals and ConnectedLife not only seamlessly integrates and provides round-the-clock availability of Apollo’s clinical AI to all “ConnectedLife with Fitbit” application users, but also will advance the application and capabilities by providing the AI with near real-time, continuous, longitudinal wellness and health data, e.g. breathing rate, heart rate, exercise, sedentary time, sleep, PROs, and as a result deliver a digital transformation from the point in time assessment to one that is continuous and dynamic in a remote, home setting.
As a result of this dynamic ConnectedLife enabled capability physicians can design and provide a patient with a personal care plan and digitally monitor patient compliance and objectively measure progression with recommended lifestyle modifications and improvement in wellness and health vitals reducing the risk of cardiac disease.
The team at ConnectedLife is at present managing the deployment of its solutions with over 50 healthcare partners worldwide and Apollo’s Clinical AICVD tool will automatically be available and operational to all customers.
In Singapore, the National University Hospital System’s Alexandra Hospital has been working with ConnectedLife to prepare for the widespread adoption and everyday application of Apollo’s Clinical AI through the ConnectedLife with Fitbit application. Together with ConnectedLife, Alexandra Hospital will collaborate with Apollo Hospitals to further the Clinical AI delivery and drive toward a healthier Singapore.
Shares of Apollo Hospitals Enterprise Ltd was last trading in BSE at ₹3882.40 as compared to the previous close of ₹3816.50. The total number of shares traded during the day was 22379 in over 3590 trades.
The stock last hit in BSE,
- Intraday High of ₹ 3932.30
- Intraday low of ₹ 3868.40